Drug Trial Radar · NCT01757795
Safety, Tolerability and Pharmacokinetics of SP-8203
Last checked: Nov 20, 2026Latest source record: Jul 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Dec 23, 2013
Primary completion
Mar 11, 2015
Study completion Mar 11, 2015
Sponsor
- Lead sponsor
- Shin Poong Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 31, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Phase I study in health volunteers to assess the safety, tolerability and pharmacokinetics of escalating single doses and multiple doses of SP-8203
Conditions
- Ischemic Stroke
Interventions
SP-8203Drug
SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
PlaceboDrug
Placebo will be intravenously administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence rate of adverse events, and adverse drug reaction in single ascending doses (SAD)Time frame: Follow-up to 7 days after administration
- The incidence rate of adverse events, and adverse drug reaction in multiple ascending doses (MAD)Time frame: Follow-up to 13 days after first administration
- Pharmacokinetics in single ascending doses (SAD)Time frame: within 3 days of administration
- Pharmacokinetics in multiple ascending doses (MAD)Time frame: within 9 days of first administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.